India has approved a 30% cap on trade margins for non-scheduled anti-cancer medicines, aiming to cut prices by up to 70% and save patients Rs 2,500 crore annually. The National Pharmaceutical Pricing Authority will notify the list after an expert committee finalises covered drugs. The move addresses mark-ups that can reach 700%.
India Caps Trade Margins on Cancer Drugs at 30%
Source: Moneycontrol